Patents cover magnesium compositions and uses for cognitive function and neurological disorders.
CITY OF INDUSTRY, Calif., Aug. 14, 2012 /PRNewswire/ — AIDP, Inc., the distributors of Magtein™ magnesium L-threonate, expected to be the next breakthrough ingredient for cognitive health, has been awarded two patents for magnesium compositions and uses for cognitive function (Patent 8,178,118) and neurological disorders (Patent 8,142,803).
The patents, titled “Magnesium compositions and uses thereof for cognitive function” (Patent 8,178,118) and “Magnesium compositions and uses thereof for neurological disorders” (Patent 8,142,803) are among the four U.S. patents awarded from seven ongoing patent applications, including international rights. These patents protect Magtein’s unique magnesium compositions and its use for any magnesium L-threonate-containing food, nutritional supplements and drugs for enhancing cognitive function or ameliorating the effects of a neurological disorder. The use of these products is applicable for improving the health of people suffering from loss of cognitive function, loss of memory, Alzheimer’s disease, depression, attention deficit hyperactivity disorder, Amyotrophic lateral sclerosis (ALS), Parkinson’s disease, migraine, anxiety disorder, and mood disorder, as some representative of cognitive and neurological disorders.
“We truly believe that Magtein is a game changing ingredient that will benefit millions of busy and stressed consumers by helping to improve their quality of life,” says Edward Lee Ph.D., AIDP president.
“AIDP, as the exclusive provider of all Magtein magnesium L-threonate, is uniquely positioned to serve the functional food and beverage marketplace to support the cognitive health category,” added Dr. Lee.
Discovered by Guosong Liu, M.D., Ph.D., and a group of scientists at Massachusetts Institute of Technology (MIT), and Tsinghua University in Beijing, China, studies on Magtein have been published in prestigious journals of neuroscience – Neuron (January 2010) and The Journal of Neuroscience (October 2011). With cognitive diseases the seventh leading cause of death in the U.S. and growing at an alarming rate, Magtein, which has self-affirmed GRAS status, is the only form of magnesium proven to significantly increase brain magnesium levels. Furthermore, animal research showed Magtein improved short-term and long-term memory as well as spatial recognition.
Dr. Liu is the president and founder of the Center for Learning and Memory, School of Medicine, Tsinghua University, Beijing, China and Adjunct Full Professor of the Center for Learning and Memory, University of Texas Austin. Dr. Liu is an investigator at the Picower Institute for Learning and Memory and is a former professor at the department of brain and cognitive science and the department of biology at MIT.
For over 15 years, AIDP, Inc. based in City of Industry, CA, has been a leader in functional ingredients for a wide-range of applications from vitamins, minerals and amino acids, to specialty and proprietary products. Pioneering breakthroughs for the research and development of proprietary ingredients for bone, joint and cognitive health under the anti-aging platform, the AIDP mission is to achieve ultimate customer satisfaction through creative product innovation and superior service.
For more information about Magtein magnesium L-threonate studies, call Kathy Lund, AIDP vice president of business development and marketing, at 303.734.0860 or visit www.AIDP.com.
PR Newswire (http://s.tt/1kN8m)